



Press release

Holger Reithinger joins the investment team of Global Life Science Ventures from the 3i Group

Munich/Zug/London, 12 October 2004 – *Global Life Science Ventures (GLSV)* today announced that Dr. Holger Reithinger has joined the GLSV investment team as Principal operating from the Munich office. Dr. Reithinger comes to GLSV from the 3i Group where he was a Director at 3i Germany's healthcare practice. In this role, he specialized in early-stage to mid-stage healthcare investments across Europe. Dr. Reithinger will provide senior level management and guidance for GLSV's growing portfolio of life science companies and will play a key role in evaluating new investment opportunities for the fund.

Dr. Hans Küpper, Partner of Global Life Science Ventures, commented: "It gives us great pleasure to welcome Dr. Reithinger to our investment team. His inside knowledge of the healthcare sector and broad network of contacts throughout Europe ideally complement our existing team of professionals." Hanns-Peter Wiese, Partner of Global Life Science Ventures, added: "Holger, whom we have known personally since 1997, has a strong track record in the venture capital industry and has served on the boards of several early-stage life science companies, some of which were supported through our first fund. His proven experience will be extremely useful as we continue to build our investment portfolio and brand name as a leading European venture capital group dedicated to the life sciences."

Dr. Reithinger holds a PhD in Biochemistry from the University of Frankfurt / Max-Planck-Institute of Biophysics where he worked on protein design in the department of Nobel Laureate Professor Dr. Hartmut Michel. At that time, Dr. Reithinger's PhD supervisor was Professor Dr. Arne Skerra, one of the founders of Pieris Proteolab AG. Pieris, a portfolio company of GLSV, was recently nominated for the German Future Prize (Deutsche Zukunftspreis) for its work on a new class of biopharmaceuticals (Anticalins). As an undergraduate, Dr. Reithinger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. He has over seven years of venture capital experience in the biotechnology industry. For three years prior to joining 3i, he was an Investment Manager at Technologieholding VC GmbH, which at the time was a leading German specialist fund for early-stage technologies. Technologieholding VC GmbH was acquired by the 3i Group in 2000. Before becoming a venture capitalist, Dr. Reithinger worked as a product development manager at Biometra/Whatman Plc, where he was responsible for the identification, development and marketing of new molecular biology products. Dr. Reithinger has served on the boards of 4SC AG, apovia AG, Epigenomics AG, which recently went public, and other companies in the life science sector.



About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 30 leading biotechnology companies, five of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global Life Science Ventures – one team – three locations – global perspective

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30
www.glsv-vc.com
mailbox@glsv-vc.com

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

UK

GLSV Ltd.
1, Northumberland Avenue
London WC2N 5BW, UK
Tel. +44 (0)20 89 38 66 92
Fax +44 (0)20 89 38 77 40

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch